Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spruce Biosciences, Inc. (“Spruce” or “the Company”) (NASDAQ: SPRB). Investors who purchased Spruce securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SPRB.

Investigation Details:

On March 13, 2024, Seeking Alpha published a report stating that the Company’s “stock plunged 75% in post-market trading Tuesday on news that the company plans to cut 21% of its workforce in the wake of a failed Phase 2 study for its drug candidate tildacerfont.” The report continues, “The biotech company said the study, called CAHmelia-203, failed to meet its primary endpoint and was being terminated as a result. The study had been evaluating tildacerfont in the treatment of adult classic congenital adrenal hyperplasia, or CAH, with severe hyperandrogenemia.” Following this news, Spruce's stock price dropped.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Spruce securities, you can assist this investigation by visiting the firm’s site: bgandg.com/SPRB. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240321755907/en/